<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053218_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134647</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012NL113051</safetyreportid>
		<primarysourcecountry>NL</primarysourcecountry>
		<occurcountry>NL</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121207</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121207</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012NL113051</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>NL</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientsex>1</patientsex>
			<reaction>
				<primarysourcereaction>Terminal condition/terminally ill</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Terminal state</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Terminal state</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>NL</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>NL</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>4 mg / 100ml once in 28 days</drugdosagetext>
				<drugdosageform>Solution For Infusion</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Prostate cancer metastatic</drugindication>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>NL</obtaindrugcountry>
				<drugbatchnumb>s0038</drugbatchnumb>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>NL</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>4 mg / 100ml once in 28 days</drugdosagetext>
				<drugdosageform>Solution For Infusion</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120706</drugstartdate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>NL</obtaindrugcountry>
				<drugbatchnumb>s0005A</drugbatchnumb>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>NL</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>4 mg / 100ml once in 28 days</drugdosagetext>
				<drugdosageform>Solution For Infusion</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121031</drugstartdate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>NL</obtaindrugcountry>
				<drugbatchnumb>s0005A</drugbatchnumb>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>NL</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>4 mg / 100ml once in 28 days</drugdosagetext>
				<drugdosageform>Solution For Infusion</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121127</drugstartdate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Terminal state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012NL113051, is an initial spontaneous report received from a consumer (patient) via marketing program (Novanurses: MPID: 1049V1; Eurocept Homecare:  EC20122326) on 07 Dec 2012. This report refers to a male patient of an unknown age (patient number: 48173). The patient received Zometa (zoledronate) for the treatment of metastasized prostate cancer from an unknown date at a dose of 4 mg / 100ml once in 28 days, intravenously. The Zometa administrations included: 06 Jul 2012 (batch s0038), 31 Oct 2012 (batch s0005A), and 27 Nov 2012 (batch s0005A). On an unknown date, the treatment with the Zometa was withdrawn because the patient was terminally ill. The outcome of the event was unknown. The seriousness and causality of the event were not reported.</narrativeincludeclinical>
				<sendercomment>MAC: Underlying malignancy likely resulted in terminal state.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
